Nearly everyone has a story about someone close to them that passed away suddenly due to cardiac arrest, or someone who had a stroke that left them disabled, no longer the person they were the day before. Management here at Lexington Biosciences is no different. Our founders and leadership team have also gotten that gut-wrenching phone call to learn of someone being hospitalized or passing away, all too often accompanied by phrases like “no one saw it coming.”
Many times, it is these types of heartbreaking events that drive people to say, “I’m going to do something about this!” That has been the mantra at our company from day one.
Everyone has his or her motivator. For CEO Eric Willis, 20+ years of developing products for patients after they were sick and seeing the ravages of heart disease inspired him to want to get in front of the condition before its got its hooks in.
It’s an unfortunate fact that 1 in every 3 deaths in the U.S. each year is at the hands of heart attack or stroke and that cardiovascular disease is the number one killer worldwide. Worse yet, for up to 50% of the 600,000 Americans that die from coronary disease every year, the very first meaningful symptom is a heart attack. Think about that. Every minute someone in the U.S. is made aware of their disease for the first time by an event that may claim their life.
Early assessment is clearly a key to prevention of conditions like atherosclerosis, or the build up of cholesterol plaque in the walls of arteries. Unfortunately, today’s healthcare strategies are mostly reactive when it comes to measuring heart disease and the existing diagnostic tools are invasive and expensive and still don’t always catch cardiovascular disease until after it’s developed.
Our mission: to change those dreadful statistics. We come to work every day focused on making a difference with the goal of one day being recognized as the company that saved countless lives with our novel technology that shifts the cardiovascular disease paradigm to being proactive, instead of reactive.
So How Are We Trying to Do It?
In future blog posts, we’ll discuss more details on the work of our flagship product, the HeartSentry. The device was aptly named to be the guardian of your heart, alerting you and your physician of potential problems before they occur.
The crux of the HeartSentry, a device somewhat similar in form to a traditional blood pressure cuff, is measuring and recording changes in the vascular endothelium as a precursor to cardiovascular disease. If we are successful in our mission, HeartSentry would be the first simple to use, inexpensive device for measuring the endothelium in clinical and eventually home settings.
We envision that for the first time ever, at-risk patients will be able to work with their doctor to measure and monitor cardiovascular health by assessing the function of the vascular endothelium – the vital innermost lining of the cardiovascular system. There is plenty of work yet to do, but our clinical research so far is extremely compelling and we are on track to commercialization upon the successful completion our ongoing pivotal clinical trial scheduled to conclude later this year.
There is plenty to be excited about as we work vigilantly to bring to market a device that we believe could have a powerful diagnostic benefit as a front-line tool to save millions of people worldwide. After all, that’s why we’re here doing what we’re doing. We don’t want to hear “no one saw it coming” anymore.
By Lexington Biosciences